Biomea Fusion (BMEA)
(Delayed Data from NSDQ)
$8.64 USD
-0.07 (-0.80%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $8.65 +0.01 (0.12%) 6:52 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.64 USD
-0.07 (-0.80%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $8.65 +0.01 (0.12%) 6:52 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Zacks News
Wall Street Analysts Think Biomea Fusion (BMEA) Could Surge 317.86%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 317.9% upside potential for Biomea Fusion (BMEA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why
by Zacks Equity Research
Biomea Fusion (BMEA) rises 41% in a month on the back of positive investor expectations regarding the clinical development of its lead candidate, BMF-219, for the type II diabetes indication.
Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up
by Zacks Equity Research
Biomea (BMEA) successfully doses the first patient in its phase I study of BMF-500 to treat adult patients with acute leukemia. The company's stock rises 6.7% on the news.
Is Ayr Wellness Inc. (AYRWF) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Ayr Wellness Inc. (AYRWF) and Biomea Fusion, Inc. (BMEA) have performed compared to their sector so far this year.
Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study
by Zacks Equity Research
Preliminary data from an ongoing mid-stage study shows that treatment with Biomea's (BMEA) lead candidate demonstrated a robust glucose-lowering response in patients with type II diabetes.
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
by Zacks Equity Research
Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.
Has Aspira Women's Health (AWH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aspira (AWH) and Biomea Fusion, Inc. (BMEA) have performed compared to their sector so far this year.
What Makes Biomea Fusion, Inc. (BMEA) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Biomea Fusion, Inc. (BMEA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Mirati (MRTX) KRAS Candidate MRTX1133 to Enter Clinical Stage
by Zacks Equity Research
Mirati Therapeutics (MRTX) announces IND clearance for oral KRASG12D selective inhibitor, MRTX1133, by the FDA. It is set to initiate phase I/II study in early 2023.
Biomea (BMEA) Begins Dosing in Lung Cancer Study, Stock Up
by Zacks Equity Research
Biomea Fusion (BMEA) announces the successful dosing of the first patient in phase I/Ib study of BMF-219 in KRAS mutant solid tumors. Stocks rise 11.69% in response.
Should You Buy Biomea Fusion (BMEA) Ahead of Earnings?
by Zacks Equity Research
Biomea Fusion (BMEA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.